A Comparison of JointRep® and Microfracture in Repair of Cartilage Lesions on the Femoral Condyle or Trochlea, (JMAC)
Primary Purpose
Chondral Defect, Articular Cartilage Defect, Articular Cartilage Disorder of Knee
Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
JointRep®
Microfracture
Sponsored by
About this trial
This is an interventional treatment trial for Chondral Defect focused on measuring Bone Marrow Stimulation, Microfracture, Matrix Augmented Bone Marrow Stimulation, Chitosan
Eligibility Criteria
Inclusion Criteria:
- Be between 18-65 years old
- Have one or two focal articular cartilage lesion(s) (ICRS Grade 3 or 4A) on the femoral condyles or trochlea of the index knee; patellar tracking must be normal if the index lesion(s) is on the trochlea. Individually, a lesion can be between 2-7cm2. If more than one lesion is present, the sum of the two lesions should not exceed 10cm2.
- Within 6 months prior to treatment, have a Magnetic Resonance Imaging (MRI) or arthroscopic confirmation of lesion(s) in the index knee.
- For patients older than 40 y.o, to have a radiological Kellgren and Lawrence (K&L) grading from a standing knee radiograph taken less than 6 months previously, Grade 1 or
- If not, an actual test will be performed as part of the visit 1 procedures.
- Have a clinically stable knee, with no ligament deficiencies (<5mm side-to-side difference on Lachman and varus/valgus stress testing & Grade 0 or 1 on Pivot shift test) and the meniscal rims are intact (a maximum of 50% resection is allowed)
- Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study
- VAS pain great than or equal to 4 in the last week.
- Be willing and able to comply with all study procedures including all preoperative, post-operative and rehabilitation requirements
- If female and of child-bearing potential, must report double-barrier, contraceptive use (e.g. use of birth-control pill and condom) for at least 2 months prior to treatment and in the 12 months following treatment.
- If female and of child-bearing potential, have a negative pregnancy test prior to the surgical procedure and no intention of becoming pregnant in the 12 months following treatment.
Exclusion Criteria:
- Have a Body Mass Index (BMI) >35kg/m2
- Have more than two lesions (ICRS grade 3 or 4A) on any surface in the index knee
- Have "kissing" or opposing lesion(s) (ICRS grade 3 or 4A) of the condyle, tibia or patella in the index knee; additional linear lesions which bear Grade 3 or 4 characteristics may be acceptable if they are determined by the Investigator to be incidental, not clinically relevant, and consistent with the subject demographic
- Have malalignment of >5 degrees varus or valgus in the index knee based on standard AP x-rays requiring an osteotomy
- Have had any surgical treatment for cartilage repair in the index knee within 1 year prior to treatment
- Have had intra-articular injections within 3 months in the index knee
- Have a diagnosis of a concomitant knee injury which may confound assessment of the index knee (e.g., important meniscal injury)
- Have significant pain emanating from other lower body joints in the ipsilateral (hip, ankle) or contralateral (hip, knee, ankle) limb.
- Have known allergies to shellfish
- Have a known history of crystalloid or inflammatory arthropathy
- Have any condition that is unrelated to the index knee and significantly impairs walking ability (e.g., spinal stenosis, sciatica)
- Have advanced musculoskeletal disease
- Have active coagulation disorders
- Are currently using antibiotics
- Are participating concurrently in another clinical investigation, or have participated in a clinical investigation within the last 90 days, or intend to participate in another clinical investigation during the course of the study
- Are currently abusing drugs or alcohol or have a history of the same within the last 12 months
- Have any mental or psychological disorder that would impair their ability to complete the study questionnaires
- Are currently breastfeeding or planning to breastfeed any time during the course of the study
- Are currently a prisoner
- Have significant comorbidities or conditions associated with high-risk for surgical or anesthetic survival (e.g., renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.)
- Have any medical condition or other circumstances, in the judgment of the investigator, that might interfere with the ability to return for follow-up visits, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative rehabilitation
- Have any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the device's safety and performance
Intra-operative Exclusion Criteria:
Subjects who meet any of the following intra-operative screening criteria will be excluded from participation in this study:
- Have lesion(s) in the index knee that are not contained (intact shoulders) and/or exceed 7 cm² in total size after debridement for a single lesion and 10cm2 for more than one lesion, if within the same condyle or the trochlea. If only a single lesion suitable to be included is identified, it might be between 2-7cm2.
Minor concomitant procedures are allowed such as, but not limited to:
- Removal of loose bodies
- Plica excision
- Minor synovial removing
- Minor chondroplasty (debridement)
- Lysis of adhesions
- Meniscal trimming/suturing which respects the exclusion criteria.
Sites / Locations
- Canberra Orthopaedics and Sports MedicineRecruiting
- Sydney Knee Specialists
- Lingard Private HospitalRecruiting
- OrthosportsRecruiting
- Cairns Orthopaedic ClinicRecruiting
- North Queensland KneeRecruiting
- Melbourne Orthopedic GroupRecruiting
- Dartmouth General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Intervention
Control
Arm Description
JointRep® plus microfracture
Microfracture alone
Outcomes
Primary Outcome Measures
Lesion fill.
Percentage of lesion fill measured by 3D quantitative Magnetic Resonance Imaging (qMRI).
Secondary Outcome Measures
Visual Analogue Scale.
Pain score in treated knee using the visual analogue scale from 0(no pain) to 10 (worst pain imaginable) .
T2 scores.
Difference in quantitative T2 scores between investigational subjects and control subjects measured by qMRI.
Treatment failure.
Proportion of subjects who do not experience a treatment failure and achieve ≥80% lesion fill (success rate).
Knee Injury and Osteoarthritis Outcome Score (KOOS).
Knee Injury and Osteoarthritis Outcome Score (pain, function, symptoms, sports/recreation and quality of life). 100 indicates no problems and 0 indicates extreme problems.
Tegner Activity Scale
Tegner activity scale provides a level of activity and is scored between 0 and 10. Level 0 is the worst activity level and Level 10 is the best activity level.
Magnetic Resonance Observation of Cartilage Repair Tissue 2.0 (MOCART-2) score.
MOCART-2 score ranges form 0 (worst outcome) to 100 (best outcome) .
Euro Quality of Life-5D (EQ-5D) instrument for measuring quality of life.
EuroQol-5D (EQ-5D) instrument for measuring quality of life has two parts. The first assesses health in five parts (mobility, self-care, usual activity, pain/discomfort, anxiety depression) with each scored form 1 (best outcome) to 5 (worst outcome). The second part consists of a visual analogue scale rating perceived health form 0 (the worst imaginable health) to 100 (the best imaginable health).
Safety as Adverse Events related to the procedure
Evaluation of adverse events.
Full Information
NCT ID
NCT04840147
First Posted
March 23, 2021
Last Updated
September 8, 2022
Sponsor
Oligo Medic Pty Ltd
Collaborators
Mobius Medical Pty Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04840147
Brief Title
A Comparison of JointRep® and Microfracture in Repair of Cartilage Lesions on the Femoral Condyle or Trochlea,
Acronym
JMAC
Official Title
A Randomized, Controlled, Comparative, Single-blinded, Multi-center Study Evaluating JointRep® and Microfracture in Repair of Focal Articular Cartilage Lesions on the Femoral Condyle or Trochlea, The JMAC Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 22, 2021 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oligo Medic Pty Ltd
Collaborators
Mobius Medical Pty Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the study is to compare whether JointRep® plus microfracture is more effective than microfracture alone when treating symptomatic focal articular cartilage lesions in the knee (femoral condyles or trochlea).
Detailed Description
The aim of the JMAC study, an international multicenter Randomized Controlled Trial, is to assess the effectiveness and safety of JointRep®, a second-generation chitosan-based hydrogel for cartilage repair. A total of 185 subjects will be randomized 2:1 to either Microfracture plus JointRep® or Microfracture alone. The follow up will be at 24 months, with a planned interim analysis at 12 months. The primary endpoint is an objectively measured structural one (quantity of new cartilaginous tissue, assessing the percentage of fill) and it will be blindly assessed using a sophisticated quantitative MRI at 12 and 24 months. Two of the secondary endpoints are also structurally based and blindly measured: quality of the new tissue, quantifying the T2 (which measures the Collagen 2 content and orientation as well as degree of hydration); the upper and lower half of the new tissue T2 measurement will depict the degree of stratification of the new cartilaginous tissue. A semiquantitative MOCART-2 blinded analysis will also be carried out. The clinical outcomes will be measured using KOOS and Tegner, as well as a VAS and an EQ-5 questionnaire. All the secondary endpoints will be analyzed at the same 12 and 24 months timepoints. In addition, subject safety will be assessed through a record of adverse events.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chondral Defect, Articular Cartilage Defect, Articular Cartilage Disorder of Knee
Keywords
Bone Marrow Stimulation, Microfracture, Matrix Augmented Bone Marrow Stimulation, Chitosan
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
185 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
JointRep® plus microfracture
Arm Title
Control
Arm Type
Other
Arm Description
Microfracture alone
Intervention Type
Device
Intervention Name(s)
JointRep®
Intervention Description
JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
Intervention Type
Procedure
Intervention Name(s)
Microfracture
Other Intervention Name(s)
Bone Marrow Stimulation
Intervention Description
Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
Primary Outcome Measure Information:
Title
Lesion fill.
Description
Percentage of lesion fill measured by 3D quantitative Magnetic Resonance Imaging (qMRI).
Time Frame
24-months post procedure.
Secondary Outcome Measure Information:
Title
Visual Analogue Scale.
Description
Pain score in treated knee using the visual analogue scale from 0(no pain) to 10 (worst pain imaginable) .
Time Frame
Baseline and then at 3-months, 6-months, 12-months and 24-months post procedure.
Title
T2 scores.
Description
Difference in quantitative T2 scores between investigational subjects and control subjects measured by qMRI.
Time Frame
12 and 24-months post procedure.
Title
Treatment failure.
Description
Proportion of subjects who do not experience a treatment failure and achieve ≥80% lesion fill (success rate).
Time Frame
24-months post procedure.
Title
Knee Injury and Osteoarthritis Outcome Score (KOOS).
Description
Knee Injury and Osteoarthritis Outcome Score (pain, function, symptoms, sports/recreation and quality of life). 100 indicates no problems and 0 indicates extreme problems.
Time Frame
6 and 12 and 24-months post procedure.
Title
Tegner Activity Scale
Description
Tegner activity scale provides a level of activity and is scored between 0 and 10. Level 0 is the worst activity level and Level 10 is the best activity level.
Time Frame
6 and 12 and 24-months post procedure.
Title
Magnetic Resonance Observation of Cartilage Repair Tissue 2.0 (MOCART-2) score.
Description
MOCART-2 score ranges form 0 (worst outcome) to 100 (best outcome) .
Time Frame
6 and 12 and 24-months post procedure.
Title
Euro Quality of Life-5D (EQ-5D) instrument for measuring quality of life.
Description
EuroQol-5D (EQ-5D) instrument for measuring quality of life has two parts. The first assesses health in five parts (mobility, self-care, usual activity, pain/discomfort, anxiety depression) with each scored form 1 (best outcome) to 5 (worst outcome). The second part consists of a visual analogue scale rating perceived health form 0 (the worst imaginable health) to 100 (the best imaginable health).
Time Frame
6 and 12 and 24-months post procedure.
Title
Safety as Adverse Events related to the procedure
Description
Evaluation of adverse events.
Time Frame
Baseline to 24-months post procedure.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Be between 18-65 years old
Have one or two focal articular cartilage lesion(s) (ICRS Grade 3 or 4A) on the femoral condyles or trochlea of the index knee; patellar tracking must be normal if the index lesion(s) is on the trochlea. Individually, a lesion can be between 2-7cm2. If more than one lesion is present, the sum of the two lesions should not exceed 10cm2.
Within 6 months prior to treatment, have a Magnetic Resonance Imaging (MRI) or arthroscopic confirmation of lesion(s) in the index knee.
For patients older than 40 y.o, to have a radiological Kellgren and Lawrence (K&L) grading from a standing knee radiograph taken less than 6 months previously, Grade 1 or
If not, an actual test will be performed as part of the visit 1 procedures.
Have a clinically stable knee, with no ligament deficiencies (<5mm side-to-side difference on Lachman and varus/valgus stress testing & Grade 0 or 1 on Pivot shift test) and the meniscal rims are intact (a maximum of 50% resection is allowed)
Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study
VAS pain great than or equal to 4 in the last week.
Be willing and able to comply with all study procedures including all preoperative, post-operative and rehabilitation requirements
If female and of child-bearing potential, must report double-barrier, contraceptive use (e.g. use of birth-control pill and condom) for at least 2 months prior to treatment and in the 12 months following treatment.
If female and of child-bearing potential, have a negative pregnancy test prior to the surgical procedure and no intention of becoming pregnant in the 12 months following treatment.
Exclusion Criteria:
Have a Body Mass Index (BMI) >35kg/m2
Have more than two lesions (ICRS grade 3 or 4A) on any surface in the index knee
Have "kissing" or opposing lesion(s) (ICRS grade 3 or 4A) of the condyle, tibia or patella in the index knee; additional linear lesions which bear Grade 3 or 4 characteristics may be acceptable if they are determined by the Investigator to be incidental, not clinically relevant, and consistent with the subject demographic
Have malalignment of >5 degrees varus or valgus in the index knee based on standard AP x-rays requiring an osteotomy
Have had any surgical treatment for cartilage repair in the index knee within 1 year prior to treatment
Have had intra-articular injections within 3 months in the index knee
Have a diagnosis of a concomitant knee injury which may confound assessment of the index knee (e.g., important meniscal injury)
Have significant pain emanating from other lower body joints in the ipsilateral (hip, ankle) or contralateral (hip, knee, ankle) limb.
Have known allergies to shellfish
Have a known history of crystalloid or inflammatory arthropathy
Have any condition that is unrelated to the index knee and significantly impairs walking ability (e.g., spinal stenosis, sciatica)
Have advanced musculoskeletal disease
Have active coagulation disorders
Are currently using antibiotics
Are participating concurrently in another clinical investigation, or have participated in a clinical investigation within the last 90 days, or intend to participate in another clinical investigation during the course of the study
Are currently abusing drugs or alcohol or have a history of the same within the last 12 months
Have any mental or psychological disorder that would impair their ability to complete the study questionnaires
Are currently breastfeeding or planning to breastfeed any time during the course of the study
Are currently a prisoner
Have significant comorbidities or conditions associated with high-risk for surgical or anesthetic survival (e.g., renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.)
Have any medical condition or other circumstances, in the judgment of the investigator, that might interfere with the ability to return for follow-up visits, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative rehabilitation
Have any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the device's safety and performance
Intra-operative Exclusion Criteria:
Subjects who meet any of the following intra-operative screening criteria will be excluded from participation in this study:
Have lesion(s) in the index knee that are not contained (intact shoulders) and/or exceed 7 cm² in total size after debridement for a single lesion and 10cm2 for more than one lesion, if within the same condyle or the trochlea. If only a single lesion suitable to be included is identified, it might be between 2-7cm2.
Minor concomitant procedures are allowed such as, but not limited to:
Removal of loose bodies
Plica excision
Minor synovial removing
Minor chondroplasty (debridement)
Lysis of adhesions
Meniscal trimming/suturing which respects the exclusion criteria.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alberto Restrepo, MD
Phone
+15142960066
Email
restrepo@oligomedic.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruce Caldwell, MBBS, FRACS
Organizational Affiliation
Lingard Private Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Canberra Orthopaedics and Sports Medicine
City
Deakin
State/Province
Australian Capital Territory
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mark Porter, MBBS, FRACS
First Name & Middle Initial & Last Name & Degree
Mark Porter, MBBS, FRACS
Facility Name
Sydney Knee Specialists
City
Kogarah
State/Province
New South Wales
Country
Australia
Individual Site Status
Active, not recruiting
Facility Name
Lingard Private Hospital
City
Newcastle
State/Province
New South Wales
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Caldwell, MBBS, FRACS
Facility Name
Orthosports
City
Randwick
State/Province
New South Wales
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Doron Sher, MBBS, FRACS
First Name & Middle Initial & Last Name & Degree
Doron Sher, MBBS, FRACS
Facility Name
Cairns Orthopaedic Clinic
City
Parramatta Park
State/Province
Queensland
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ben Parkinson, MBBS, FRACS
First Name & Middle Initial & Last Name & Degree
Ben Parkinson, MBBS, FRACS
Facility Name
North Queensland Knee
City
Pimlico
State/Province
Queensland
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter McEwen, MBBS, FRACS
First Name & Middle Initial & Last Name & Degree
Peter McEwen, MBBS, FRACS
Facility Name
Melbourne Orthopedic Group
City
Melbourne
State/Province
Victoria
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Timothy Lording, MBBS, FRACS
First Name & Middle Initial & Last Name & Degree
Timothy Lording, MBBS, FRACS
First Name & Middle Initial & Last Name & Degree
Ashley Carr, MBBS, FRACS
First Name & Middle Initial & Last Name & Degree
Jit Balakumar, MBBS, FRACS
First Name & Middle Initial & Last Name & Degree
Mark O'Sullivan, MBBS, FRACS
Facility Name
Dartmouth General Hospital
City
Dartmouth
State/Province
Nova Scotia
ZIP/Postal Code
B2Y 4G8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jasmine Boudreau
Email
jsmnboudreau@gmail.com
First Name & Middle Initial & Last Name & Degree
Nathan Urquhart, MD, FRCSC
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Comparison of JointRep® and Microfracture in Repair of Cartilage Lesions on the Femoral Condyle or Trochlea,
We'll reach out to this number within 24 hrs